Dr. Fleming Discusses Importance of QoL in Prostate Cancer

Mark T. Fleming, MD
Published: Friday, Mar 01, 2019



Mark T. Fleming, MD, medical oncologist, Virginia Oncology Associates, associate chair, Genitourinary Research Committee, US Oncology Network, discusses the focus on quality of life (QoL) in recent prostate cancer clinical trials.

The treatment of prostate cancer has essentially circled back from where it started, Fleming says. When docetaxel was first FDA-approved in 2014 for the treatment of patients with metastatic hormone-sensitive disease, there was a QoL component that garnered attention due to the traditional belief that chemotherapy is detrimental towards QoL.

This is particularly important to remember for asymptomatic patients because physicians need to balance how they tolerate treatment with its efficacy. In today’s landscape, physicians are having more in-depth conversations with their patients in terms of tolerability, cost, and other important factors in order to inform treatment decisions, Fleming says.
SELECTED
LANGUAGE


Mark T. Fleming, MD, medical oncologist, Virginia Oncology Associates, associate chair, Genitourinary Research Committee, US Oncology Network, discusses the focus on quality of life (QoL) in recent prostate cancer clinical trials.

The treatment of prostate cancer has essentially circled back from where it started, Fleming says. When docetaxel was first FDA-approved in 2014 for the treatment of patients with metastatic hormone-sensitive disease, there was a QoL component that garnered attention due to the traditional belief that chemotherapy is detrimental towards QoL.

This is particularly important to remember for asymptomatic patients because physicians need to balance how they tolerate treatment with its efficacy. In today’s landscape, physicians are having more in-depth conversations with their patients in terms of tolerability, cost, and other important factors in order to inform treatment decisions, Fleming says.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Current Perspectives on Preventing and Managing Tumor Lysis SyndromeJun 30, 20191.0
Community Practice Connections™: 2nd Annual International Congress on Oncology Pathology™Aug 31, 20191.5
Publication Bottom Border
Border Publication
x